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Objectives: The majority of people with suspected genetic dystonia remain undiagnosed after maximal investigation, imply-
ing that a number of causative genes have not yet been recognized. We aimed to investigate this paucity of diagnoses.
Methods: We undertook weighted burden analysis of whole-exome sequencing (WES) data from 138 individuals with
unresolved generalized dystonia of suspected genetic etiology, followed by additional case-finding from international
databases, first for the gene implicated by the burden analysis (VPS16), and then for other functionally related genes.
Electron microscopy was performed on patient-derived cells.
Results: Analysis revealed a significant burden for VPS16 (Fisher’s exact test p value, 6.9 × 109). VPS16 encodes a sub-
unit of the homotypic fusion and vacuole protein sorting (HOPS) complex, which plays a key role in autophagosome-
lysosome fusion. A total of 18 individuals harboring heterozygous loss-of-function VPS16 variants, and one with a
microdeletion, were identified. These individuals experienced early onset progressive dystonia with predominant cervi-
cal, bulbar, orofacial, and upper limb involvement. Some patients had a more complex phenotype with additional neu-
ropsychiatric and/or developmental comorbidities. We also identified biallelic loss-of-function variants in VPS41,
another HOPS-complex encoding gene, in an individual with infantile-onset generalized dystonia. Electron microscopy
of patient-derived lymphocytes and fibroblasts from both patients with VPS16 and VPS41 showed vacuolar abnormali-
ties suggestive of impaired lysosomal function.
Interpretation: Our study strongly supports a role for HOPS complex dysfunction in the pathogenesis of dystonia,
although variants in different subunits display different phenotypic and inheritance characteristics.
ANN NEUROL 2020;88:867–877
Dystonia is a common movement disorder associatedwith significant disability and increased risk of mor-
tality.1,2 It is characterized by sustained or episodic muscle
contractions, which cause abnormal, often repetitive move-
ments and twisting postures affecting the limbs, trunk,
neck, and face.3 Despite significant advances in next-
generation sequencing technologies, over 85% of people
with suspected genetic dystonia remain undiagnosed after
whole-genome sequencing,4 implying that the majority of
genetic dystonias currently remain unrecognized. The rea-
sons for this are multifactorial, attributed to locus heteroge-
neity, incomplete disease penetrance, and the current
limitations of next-generation sequencing technologies.
Here, we report a cohort of individuals with loss-of-
function (LOF) mutations in 2 components of the homo-
typic fusion and vacuole protein sorting (HOPS) complex, a
highly conserved complex required for endosome-lysosome
and autophagosome-lysosome fusion.5 We describe a series
of patients with generalized dystonia associated with hetero-
zygous LOF variants in VPS16 and also report biallelic LOF
variants in a second HOPS complex gene, VPS41, in a child
with a severe infant-onset dystonic disorder.
Subjects and Methods
Generalized Dystonia Cohort for Burden
Analysis
A consecutive series of 138 unrelated individuals with generalized
dystonia (57 men and 81 women, all self-identifying as
European) was recruited into the study. Diagnoses were
established in accordance with the dystonia consensus criteria3 at
movement disorder specialty centers in Austria, Czechia, and
Germany. The clinical characteristics of the cohort are
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summarized in Supplementary Table S1. We excluded patients
from the cohort who had (i) a known genetic diagnosis or (ii) an
acquired form of the disease.
Whole-Exome Sequencing
The generalized dystonia cohort underwent whole-exome
sequencing (WES) at the Helmholtz Center Munich (Munich,
Germany) according to previously described methods.6 In brief,
the exonic portions of genomic DNA were enriched in solution
and indexed with Agilent (Agilent Technologies) SureSelect
Human All Exon kits, version 5 and 6. Sequencing was carried
out as 100-bp paired-end runs with HiSeq2500/4000 equipment
(Illumina). Read processing and variant annotation used an in-
house pipeline based on BWA, SAMtools, PINDEL, GATK,
ExomeDepth, and custom scripts (Helmholtz Center Munich
and Technical University of Munich). Variant filtering was done
per standard pipeline analyses, integrating data from online
repositories (1000 Genomes Project, gnomAD, dbSNP, ClinVar,
and HGMD) and in-house control-exome collections. For the
138 exomes, we obtained on average 13.6 Gb of sequence,
resulting in a mean read depth of 143.6-fold with 98.6% of the
target nucleotides covered at least 20-fold. Sequences were visual-
ized with IGV. Across the cohort, the exome data were used to
exclude causative variants in known disease genes, as described.6
Case–Control Rare-Variant Collapsing Analysis
(Burden Test)
Gene-based collapsing analysis of rare variants in patients with
dystonia versus controls was performed using TRAPD (Test Rare
vAriants with Public Data),7 a robust method for detecting
gene-disease associations.8 We searched for genes with excess
mutational burden by comparing genotype counts from 138 gen-
eralized dystonia cases with those from gnomAD control subjects
(non-Finish European [NFE] cohort, N = 64,603). We coded
case and control subjects according to the presence or absence of
at least one qualifying variant in any of the 20,000 consensus
coding sequence (CCDS) genes and focused on the following
genetic models: (1) dominant LOF, in which qualifying variants
were defined as stop-gain, frameshift, and splice-site-altering (± 2
nucleotides of exon boundary) alleles; and (2) dominant non-
synonymous, in which qualifying variants were defined as LOF
and missense alleles. The minor allele frequency (MAF) thresh-
old of qualifying variants was set at < 0.0005, with the frequency
of minor alleles determined from gnomAD (NFE cohort) and
4,000 non-neurological in-house control exomes for variants
present in dystonia case subjects, and in gnomAD (NFE cohort)
for variants present in control subjects. To detect differences in
the carrier rate of qualifying variants between case and control
subjects, we used a one-sided Fisher’s exact test. Exome-wide sig-
nificance was defined at a p value of < 1.25 × 106, correcting for
20,000 CCDS genes studied in two individual case-control
comparisons. To avoid spurious results, we undertook extensive
quality control and harmonization analyses, as described ear-
lier7,8: (i) variants overlapping low-complexity regions were fil-
tered out; (ii) sites with a read depth of < 10-fold in either of the
2 cohorts were ignored; and (iii) rare synonymous variant burden
testing was conducted. On the basis of the latter, only the top
85% of sites in terms of quality-by-depth (QD) scores for the
case sequencing cohort and the top 95% of sites in terms of QD
scores for gnomAD were included in the analysis.
Identification of Additional Cases
Using GeneMatcher9 and direct communications, international
collaborators were requested to screen their genomic databases for
additional cases. Details of the WES/whole genome sequencing
(WGS) methods used differed slightly among each center and can
be provided on request. Cases were identified from the UCL
Great Ormond Street Institute of Child Health neurogenetic
movement disorders cohort (London, UK); the Kolling Institute
of Medical Research (Sydney, Australia); the Carlo Besta Neuro-
logical Institute (Milan, Italy); the Koios Database of the Queen
Square Genomics Group at University College London (London,
UK); the Genomics England 100 K Genomes Project dataset
(UK), and Radboud University Medical Centre (Nijmegen, The
Netherlands). Databases from Cardiff (Wales) and Dublin
(Ireland) were also checked but no additional cases were found
there. Variants identified through WGS or WES and familial seg-
regation were verified by Sanger sequencing. Details of protocols,
reagents, and primer sequences are available on request. All vari-
ants are given with reference to the GRCh38 build.
We subsequently undertook a targeted search of the data-
bases above for any additional individuals with mutations affect-
ing other HOPS complex genes not previously associated with
disease, namely VPS18, VPS39, and VPS41.
Electron Microscopy
Whole blood samples were obtained in EDTA and centrifuged
to produce a buffy coat. Patient fibroblasts were obtained from
skin biopsies and cultured in Ham’s F10 medium with 12% fetal
calf serum. Penicillin and streptomycin were added to the
medium for transfer of fibroblasts. Following culture, cells were
disaggregated using 0.2% trypsin for microscopy, then cen-
trifuged to form solid clusters. Clusters were fixed in 2.5% glu-
taraldehyde in 0.1 M cacodylate buffer followed by secondary
fixation in osmium tetroxide. Tissues were dehydrated in graded
ethanol, transferred to an intermediate reagent, propylene oxide,
and then infiltrated and embedded in Agar 100 epoxy resin.
Polymerization was undertaken at 60C for 48 hours. Ninety
(90) nm ultrathin sections were cut using a Diatome diamond
knife on a Leica Ultracut UCT microtome. Sections were trans-
ferred to copper grids and stained with alcoholic uranyl acetate
and Reynolds lead citrate. The fibroblasts were examined using a
JEOL 1400 transmission electron microscope.
Ethics
Ethical approval for genetic research was obtained by each center
separately as follows: Great Ormond Street (Family 7): approved
by the London Bloomsbury Research Ethics Committee (ref: 13
/LO/0168); Generalized dystonia cohort including Fami-
lies 1–6: all subjects provided written informed consent, and the
study protocol was approved by the institutional ethics review
boards at the Technical University of Munich, Medical
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University Innsbruck, and Charles University in Prague; Kolling
Institute of Medical Research, Northern Sydney Local Health
District (Families 8 and 9): reference number RESP/15/314,
HREC/15/HAWKE/434; UCL Queen’s Square Institute of
Neurology, London (Family 10); other families recruited from
the Carlos Besta Neurology Institute, Milan (Families 11 and
12); Radboud University Medical Centre, Nijmegen (Family
13); and Genomics England (the 100 K Genomes Project; Fam-
ily 14) under ethical approval gained by those institutions.
Written informed consent was obtained from patients or
their legal guardians for participation with separate consent for
publication of recognizable images/videos or invasive procedures,
such as skin biopsy where appropriate.
Results
Weighted Burden Analysis and Case
Identification
The weighted burden analysis of 138 individuals with etio-
logically unresolved generalized dystonia (Supplementary
Table S1) identified a single study-wide significant signal,
VPS16, with a Fisher’s exact test p value of 6.9 × 10-9
(Fig 1, Supplementary Table S2). In addition to
5 heterozygous LOF alleles uncovered in the burden test
(carrier rate of 3.6% in case subjects), we found one indi-
vidual with a VPS16-encompassing microdeletion in the
cohort. Through international collaboration, an additional
13 cases with heterozygous LOF variants in VPS16 were
identified. All 19 patients (from 14 families) had VPS16
variants predicted to result in haploinsufficiency (Table 1,
Supplementary Table S3). One proband (Patient 14) had a
second, non-truncating VPS16 variant but phasing of the
variants could not be established as parental samples were
unavailable. For the other 18 probands, detailed genomic
analysis did not identify a second potentially pathogenic
VPS16 variant. Moreover, 9 individuals from
5 multigenerational families (Families 3, 7, 8, 9, and 13)
confirmed a clearly dominant pattern of disease inheritance
(Fig 2). Segregation analysis was possible in 9 families: of
these, de novo occurrence was confirmed in 1 family;
inheritance from a symptomatic parent was found in 4 fam-
ilies; and inheritance from an apparently nonmanifesting
parent in 4 families, indicating incomplete penetrance.
Clinical Features of Patients With VPS16
Affected individuals presented with a progressive early onset
dystonia (median age 12 years, range 3–50 years), with prom-
inent oromandibular, bulbar, cervical, and upper limb
involvement (Fig 3A, Tables 2 and 3). Progressive generaliza-
tion ensued in most cases, although most remained ambulant,
and only a minority (16%) lost the ability to walk in adult-
hood (Supplementary Videos S1–S3). Additional clinical fea-
tures of mild to moderate intellectual disability and
neuropsychiatric symptoms were present in approximately
one-third of patients, and 50% of families had a positive fam-
ily history of dystonia (Supplementary Table S4). A degree of
interfamilial and intrafamilial phenotypic variability was evi-
dent, both with regard to age of symptom onset and dystonia
severity. Routine diagnostic testing was unremarkable. In
4 individuals, magnetic resonance imaging (MRI) showed
bilateral and symmetrical hypointensity of the globi pallidi
and sometimes also the midbrain and dentate nuclei on MRI
sequences known to demonstrate susceptibility (T2-weighted,
T2*-weighted, and susceptibility-weighted datasets), sugges-
tive of iron deposition.10 Mild generalized cerebral atrophy
was also apparent in 4 individuals. Although not grossly
abnormal, caudate nuclei and putamina appeared relatively
small and bright on T2 (Fig 3B, see Supplementary
Table S4). Some patients had a partial response to levodopa,
trihexyphenidyl, and/or botulinum toxin type A injections.
Deep-brain stimulation was also beneficial for some, but not
all patients; sustained improvement in motor and disability
scores for the Burke-Fahn-Marsden Dystonia Rating Scale
were observed for Patient 7C (Supplementary Video S4,
Supplementary Table S5).
FIGURE 1: Weighted burden analysis. Expected versus
observed p values of the loss-of-function model are shown for
exome-wide gene collapsing analysis in a cohort of
138 individuals with generalized dystonia and gnomAD
controls (64,603 non-Finish European subjects). A Fisher’s
exact test was used to determine differences in the carrier rate
of qualifying variants between cases and controls. Qualifying
variants were defined as stop-gain, frameshift, and essential
splice-site variants with a minor allele frequency of < 0.0005,
whereas exome-wide significance was set to a p value of
< 1.25 × 10−6 (Bonferroni-corrected threshold, see Methods).
We observed a significant mutational burden (minimal genomic
inflation) for VPS16, in which 5 individuals with dystonia had a
qualifying variant. The signal and corresponding Fisher’s exact
test p value for VPS16 is indicated. [Color figure can be viewed
at www.annalsofneurology.org]
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Identification and Characterization of Individuals
With Biallelic VPS41 Variants
Screening databases for potentially pathogenic variants in
HOPS complex genes not previously implicated in disease
(VPS18, VPS39, and VPS41) identified one proband from a
consanguineous family with a homozygous canonical splic-
ing variant (NM_014396.3:c.450 + 1G > T) in VPS41,
resulting in exon 7 skipping and loss of 22 amino acid
TABLE 1. Genomic Characteristics of VPS16 Variants Identified
Genomic position cDNA variant Effect on protein Variant type Family number
chr20:2835462–3974387 NA Microdeletion CNV 6
chr20:2860515 c.436del p.Ile146Serfs*65 Frameshift 9
chr20:2860534–2860541 c.455_462dup p.Leu155Alafs*59 Frameshift 13
chr20:2860792 c.559C > T p.Arg187* Stop-gain 4, 10
chr20:2862601–2862602 c.1094_1095dup p.Tyr366Serfs*12 Frameshift 7
chr20:2863068 c.1335 T > G p.Tyr455* Stop-gain 3
chr20:2863102 c.1367 + 2 T > C p.? Splice site loss 8
chr20:2864178 c.1612-1G > C p.? Splice site loss 14
chr20:2864288 c.1720 + 1G > C p.? Splice site loss 11
chr20:2864631 c.1903C > T p.Arg635* Stop-gain 1, 2, 12
chr20:2865039–2865040 c.1988_1989insG p.Asn663Lysfs*2 Frameshift 5
CNV = copy number variant; NA = all variants are described with reference to build GRCh38, transcript NM_022575.3.
FIGURE 2: Pedigrees of families affected by VPS16 dystonia, showing autosomal dominant inheritance. Key: circle = female;
square = male; black-filled shape = individual affected by dystonia; grey-filled shape = individual may have been affected by
dystonia; diagonal slash = individual deceased; ? = number/status of additional siblings not known.
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residues (p.Ile129_Lys150del; Fig 4). This patient presented
in infancy with global developmental delay and generalized
dystonia. He attained a few words of speech and voluntary
limb movements but never sat unsupported. He had pale
optic discs and an axonal neuropathy. From 6 years of
age, his condition began to deteriorate, with reduced
motor abilities and alertness. An MRI of the brain showed
atrophy of the superior cerebellar vermis and slimming of
the posterior limb of the corpus callosum (Fig 4).
Electron Microscopy
Electron microscopy (EM) was performed on patient-
derived fibroblasts and peripheral lymphocytes from
patients with both VPS16 and VPS41 mutations in order
to determine the impact on lysosomal and vacuolar mor-
phology. When compared to age-matched controls, VPS16
patient cells (fibroblasts n = 6; and lymphocytes n = 4) con-
tained increased clusters of vacuoles, with some containing
inclusions in the form of particulate or laminated material
(Fig 5, see Supplementary Fig S1). EM analysis of patient-
derived fibroblasts and lymphocytes from the patient with
VPS41 showed numerous membrane-bound vacuoles con-
taining granular material and, in some cases, fine electron-
dense laminated strands. A large number of small pinocytic
vesicles arising from the plasma membrane were also seen.
In both VPS16-related and VPS41-related disease, the EM
changes seen in patient-derived tissue were consistent with
lysosomal dysfunction.
Discussion
We report a cohort of 20 individuals with mutations in
2 related genes, VPS16 and VPS41, which encode vacuolar
protein sorting-associated proteins 16 and 41, respectively,
both key components of the HOPS complex. The HOPS
complex mediates autophagosome-lysosome and endosome-
lysosome fusion through several different interactions with
SNARE proteins, including catalyzing the formation of the
SNARE complex11 and protection of the trans-SNARE com-
plex from disassembly once formed (Fig 6).12
Our observation of incomplete penetrance in
VPS16-related disease (a common hindrance to gene discov-
ery) suggests that, like most other genetic dystonias,13 addi-
tional genetic, epigenetic, and/or environmental factors are
likely to play an important role in disease manifestation.
Indeed, weighted burden analysis suggests a wider role for
VPS16 in conferring genetic susceptibility in a broader group
of patients with dystonia. Although adolescent-onset dystonia
has been reported in a single family harboring a homozygous
missense mutation in VPS16,14 our data suggest that VPS16
haploinsufficiency (dominant inheritance with incomplete
penetrance) is a much more common genetic mechanism for
VPS16-related disease.
Autosomal dominant VPS16-related disease appears
to be an early-onset, progressively generalizing dystonia,
which may occur in isolation or in combination with neu-
ropsychiatric and neurodevelopmental features. In this
FIGURE 3: Clinical photographs showing dystonic posturing in VPS16 patient cohort. (A) (i) Patient 9 F demonstrating orofacial
dystonia elicited during speech; (ii) Patient 11 S1 showing cervical dystonia; (iii) Patient 12 showing upper limb posturing;
(iv) Patient 11 S1 showing hand posturing; (v) Patient 12 showing spontaneous striatal toe on the left; (vi) Patient 12 as an adult,
standing, showing exaggerated lumbar lordosis; and (vii) Patient 12 as an adult, standing, showing involuntary plantar flexion/
tiptoe posture. (B) Selected MRI brain images for patients with VPS16 dystonia. Abnormalities indicated by white arrows.
(i) Axial T2 image from Patient 7 M (aged 34 years, pre-DBS) shows hypointensity consistent with iron deposition in the globi
pallidi; (ii) susceptibility-weighted images (SWIs) from Patient 7 M showing hypointensity in the midbrain nuclei (above) and
dentate nucleus of the cerebellum (below); (iii) axial SWI from Patient 7 M showing hypointensity of the globi pallidi; (iv) axial T2
image from Patient 1 (aged 10 years) showing hypointensity of the globi pallidi; (v) subtle generalized atrophy in Patient 9 F,
demonstrated in a coronal T2 image of the cerebrum (above) and a sagittal T1 image of the cerebellum (below); (vi) axial SWI
from Patient 10, aged 32 years, showing hypointensity in the globi pallidi; (vii) enlarged axial T2 image from Patient 13 F, aged
55 years, showing relatively small, bright caudates, and putamina; and (viii) axial SWI image from Patient 3 P (aged 21 years)
showing hypointensity of the midbrain nuclei. [Color figure can be viewed at www.annalsofneurology.org]
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study, it clinically resembles other “classic” genetic dys-
tonias, such as those related to KMT2B or TOR1A:
indeed, at least 1 family (Family 7) in our study had ini-
tially been referred for KMT2B testing. Radiologically,
too, there is a degree of overlap with KMT2B disease, with
basal ganglia hypointensity seen on T2 (and other related
MRI sequences) in a proportion of patients15: whether
this reflects a common pathophysiological mechanistic end
point remains to be determined. Our series does not iden-
tify any therapeutic option as reliably beneficial for all
patients with VPS16-related disease but it is notable that
some patients did derive significant benefit from deep
brain stimulation (DBS), a treatment that has also proved
very useful for both TOR1A and KMT2B-affected
patients. Three patients also reported some degree of levo-
dopa responsivity, which, although far from conclusive,
may be worth pursuing for mutation-positive patients.
There are clear differences between VPS16-related
and VPS41-related disease, although both involve subunits
of the HOPS complex and manifest with dystonia as a
prominent symptom. Whereas the cases of VPS16-related
dystonia we report involve monoallelic variants, predicted
to cause haploinsufficiency, the child with VPS41-related
disease has biallelic LOF mutations. He also has a corre-
spondingly more profound phenotype, with very early
onset of symptoms (presentation in infancy compared to
the VPS16 patient cohort, median age of presentation
12 years), severe neurodevelopmental impairment, and
evidence of clinical deterioration from during childhood.
The differing MRI findings (cerebellar vermis atrophy in
VPS41 vs subtle basal ganglia changes in VPS16) also sug-
gest some divergence of pathophysiological pathways. Cor-
roborating our findings, we note that a paper not yet
published but recently deposited with bioRxiv describes
TABLE 2. Probands’ Variants and Demographic Characteristics
Family Patient Mutation Inheritance* Sex Current age, yr
1 1 p.Arg635* NK M 27
2 2 p.Arg635* NK F 42
3 3P p.Tyr455* I-AP F 24
3Aunt F 50
4 4 p.Arg187* I-AP M 26
5 5 p.Asn663 Lysfs*2 NK M 38
6 6 Micro-deletion:
chr20:2835462–3974387
DN F 21
7 7 M p.Tyr366 Serfs*12 I-SP F 45
7C M 26
8 8 c.1367 + 2 T > C I-SP F 69
9 9F p.Ile146 Serfs*65 I-SP M 62
9C M 30
10 10 p.Arg187* NK M 32
11 11S1 c.1720 + 1 G > C I-AP M 30
11S2 M 24
12 12 p.Arg635* I-AP M 33
13 13F p.Leu155Alafs*59 I-SP M 58
13C F 17
14 14 c.1612–1 G > C NK M 57
Patient identifiers: XC = child; XF = father; XM = mother; XP = proband; XS = sibling.
DN = de novo; F = female; I-AP = inherited from asymptomatic parent; I-SP = inheritance from symptomatic parent; M = male; NK = not known.
*For multigenerational families, inheritance refers to the younger affected generation.
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TABLE 3. Features of Probands’ Dystonia
Patient
Age of
dystonia
onset, yr
Initial movement
disorder
Current movement disorder
Helpful interventionsAxial Limb Facial/ bulbar Ambulant?
1 10 Cervical dystonia Y Y (R >
L)
Y (severe speech
involvement)
Y DBS (partial
improvement)
2 13 Writer’s cramp Y (mild) Y (U >
Lo)
N Y N
3 P 17 Upper limb dystonia
(R)
Y Y Y (severe speech
involvement)
N (lost in
adulthood)
N
3 Aunt 4 Upper limb dystonia
(R)
Y Y (U
only)
Yes (speech
involvement)
Y Levodopa (minor
improvement); sensory
trick
4 15 Speech involvement
then cervical dystonia
Y Y (U
only)
Y Y N
5 30 Cervical dystonia Y Y (U
only)
Y Y N
6 11 Upper limb dystonia
(R)
Y Y (U >
Lo)
Y Y N
7 M 19 Lower limb dystonia
(R)
Y Y Y N (lost in
adulthood)
DBS (significant
improvement)
7 C 11 Facial + cervical
dystonia
Y Y (mild;
U > Lo)
Y Y (with
difficulty)
DBS (significant
improvement)
8 7 Cervical + upper +
lower limb (R) dystonia
Y Y (U and
Lo)
Y (marked
dysphonia)
Y Levodopa; Botox
Sensory trick
9 F 14 Oromandibular
dystonia
Y
(cervical)
Y (U and
Lo)
Y (dysphonia;
blepharospasm)
Y Levodopa; Botox
Sensory trick
9 C Unknown Oromandibular
dystonia
Y
(cervical)
N Y (blepharospasm;
oromandibular)
Y N
10 19 Oromandibular
dystonia
Y
(cervical)
Y (mild;
U only)
Y (laryngeal) Y TXY; Botox
Sensory trick
11 S1 8 Writer’s cramp Y
(cervical)
Y (U >
Lo)
Y (severe
dysphonia)
Y Botox (larynx)
11 S2 7 Writer’s cramp N Y (Lo >
U)
Y (dysphonia;
oromandibular)
Y N (DBS no use)
12 3 Speech involvement Y Y Yes (anarthria) N (lost age
20y)
N (DBS no use)
13 F 50 Cervical dystonia Y Y (U >
Lo)
N Y (with
difficulty)
13 C 9 Lower limb dystonia
(R)
N Y N Y TXY
14 14 Cervical dystonia +
speech involvement
Y Y (U >
Lo)
Y Y Botox
Sensory trick
Botox = botulinum toxin type A; DBS = deep brain stimulation; L = left; Lo = lower; R = right; TXY = trihexyphenidyl; U = upper.
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an additional family where 2 siblings with homozygous mis-
sense variants in VPS41 were affected by dystonia and ataxia,
with similar MRI findings to our proband, and lysosomal
abnormalities in patient-derived fibroblasts.16 Thus, our
study further supports the emerging role of biallelic LOF
VPS41 mutations in early-onset movement disorders.
The microscopic vacuolar changes we observed in
both VPS16 and VPS41-patient-derived cells are consistent
with lysosomal dysfunction. Vacuolar changes have
also been observed in fibroblasts from patients with
mucopolysaccharidosis-plus syndrome due to biallelic vari-
ants in VPS33A, another subunit of the HOPS complex.17
These observations are in keeping with in vitro studies on
human cell lines, where depletion of both VPS1618 and
VPS4119 have been separately shown to impair endosomal-
lysosomal fusion. Furthermore, the accumulation of vacu-
oles has been observed in Drosophila pigment cells in a
dVps16A knockdown model20 and yeast cells expressing
mutant vps41 protein are reported to contain many small
membrane-bound compartments.21 It has been suggested
that VPS41, through its contribution to autophagocytosis,
plays a role in suppression of neurodegenerative processes,
especially those mediated by toxic accumulation of aberrant
proteins: overexpression of human VPS41 has been shown
FIGURE 4: Features of proband with VPS41-related condition. (A) Pedigree of the VPS41 patient’s family: the proband is indicated
with an arrow. Key: circle = female; square = male; filled shape = affected individual; double horizontal line = consanguineous union.
(B) Sequencing chromatogram for cDNA of VPS41: top row shows wild-type reference sequence and second row shows results from
Sanger sequencing of patient cDNA. Bases corresponding to Exon 7 are absent in the patient. (C) T2-weighted midline sagittal MRI
brain scan from VPS41 proband. Note thinning of posterior aspect of corpus callosum (black arrow) and atrophy of superior
cerebellar vermis (white arrow). [Color figure can be viewed at www.annalsofneurology.org]
FIGURE 5: Representative electron microscopy images of patient-derived and control cells. (A) (i) Control fibroblast from a healthy
individual. (ii) From Patient 8; (iii) from Patient 11 S2; black rectangles in (ii) and (iii) indicate the region enlarged in the following
image. (B) Representative electron microscopy images of VPS41 patient-derived cells. (i) Lymphocyte, showing small vacuoles and
multivesicular bodies; (ii) fibroblast showing numerous small intracellular and membrane-abutting vesicles; (iii) fibroblast showing
vacuoles containing inclusions. Black rectangles in (i) and (iii) indicate the region enlarged in the following image. ER = endoplasmic
reticulum; MB = multivesicular bodies; SVs = small vesicles PV: pinocytic vesicles; Vacs = vacuoles.
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to be protective in Caenorhabditis elegans models of both
Parkinson’s22 and Alzheimer’s diseases.23
Although other components of the HOPS complex have
been reported in human disease (specifically VPS33A in
mucopolysaccharidosis-plus syndrome17 and VPS11 in
hypomyelinating leukodystrophy type 12)24 unlike VPS16 and
VPS41, none have been associated with dystonia phenotypes,
thereby identifying a new pathway in dystonia pathogenesis.
We postulate that impairment of endosomal-lysosomal fusion
may hinder key cellular processes within core neural networks
governing motor control (see Fig 6). Overall, our study pro-
vides compelling evidence for the role of VPS16 and VPS41 in
the physiological control of movement, mediated through its
role in the HOPS complex and lysosomal function.
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